Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AL8326 |
Synonyms | |
Therapy Description |
AL8326 is a tyrosine kinase inhibitor that inhibits Aurora B, Fgfr, and Vegfr, potentially leading to disrupted chromosome segregation, impaired cell division, decreased tumor cell proliferation, and antitumor activity (J Clin Oncol 41, 2023 (suppl 16; abstr 8585), NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AL8326 | AL-8326|AL 8326 | Aurkb Inhibitors 21 FGFR Inhibitor (Pan) 26 VEGFR Inhibitor (Pan) 36 | AL8326 is a tyrosine kinase inhibitor that inhibits Aurora B, Fgfr, and Vegfr, potentially leading to disrupted chromosome segregation, impaired cell division, decreased tumor cell proliferation, and antitumor activity (J Clin Oncol 41, 2023 (suppl 16; abstr 8585), NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05363280 | Phase II | AL8326 | AL8326 in SCLC Treatment | Recruiting | USA | 0 |